ELI LILLY & CO reported that its experimental drug retatrutide helped patients lose 28.3% of their body weight over 80 weeks. The late-stage trial results for the "triple G" medication exceed the 15-20% weight loss typically seen with current market leaders. This data strengthens Lilly's position to challenge the dominance of NOVO-NORDISK A/S-SPONS ADR in the global obesity market.
Lilly retatrutide trial shows 28 percent weight loss
Eli Lilly reported its experimental drug retatrutide helped patients lose 28.3 percent of body weight over 80 weeks. The firm plans a market launch next year.
Xurve View
洞察:
Xurve View











